INmune Bio

INMB

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

INmune Bio is a small biotechnology company focused on developing drugs that target inflammation in the brain. Its main drug candidate, XPro1595, is being tested as a potential treatment for Alzheimer's disease by targeting a protein called TNF that drives harmful brain inflammation. The company's customers are ultimately patients with neurological diseases, and it operates in the clinical-stage drug development industry.

INmune Bio does not yet sell any products, so it earns no revenue and funds its operations through stock offerings and other financing. It is based in the United States and conducts clinical trials globally, though it remains a small, pre-revenue company with a market cap near zero. The key growth driver is whether XPro1595 succeeds in clinical trials, but the main risk is that most experimental drugs fail before reaching approval, and the company must keep raising money to survive while results are pending.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+95.2% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

16.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~16 months

$19M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-99.2%

Weak — -99.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial